CN110167575B - 因子xa衍生物的制备 - Google Patents

因子xa衍生物的制备 Download PDF

Info

Publication number
CN110167575B
CN110167575B CN201780041530.2A CN201780041530A CN110167575B CN 110167575 B CN110167575 B CN 110167575B CN 201780041530 A CN201780041530 A CN 201780041530A CN 110167575 B CN110167575 B CN 110167575B
Authority
CN
China
Prior art keywords
gly
glu
lys
thr
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780041530.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN110167575A (zh
Inventor
马克·卡巴兹
帕梅拉·B·康利
卢根民
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Portola Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60663351&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN110167575(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alexion Pharmaceuticals Inc, Portola Pharmaceuticals LLC filed Critical Alexion Pharmaceuticals Inc
Priority to CN202310427500.2A priority Critical patent/CN116425860B/zh
Priority to CN202410192888.7A priority patent/CN118271391A/zh
Publication of CN110167575A publication Critical patent/CN110167575A/zh
Application granted granted Critical
Publication of CN110167575B publication Critical patent/CN110167575B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201780041530.2A 2016-06-17 2017-06-19 因子xa衍生物的制备 Active CN110167575B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202310427500.2A CN116425860B (zh) 2016-06-17 2017-06-19 因子xa衍生物的制备
CN202410192888.7A CN118271391A (zh) 2016-06-17 2017-06-19 因子xa衍生物的制备

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662351841P 2016-06-17 2016-06-17
US62/351,841 2016-06-17
PCT/US2017/038169 WO2017219034A2 (en) 2016-06-17 2017-06-19 Preparation of factor xa derivatives

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202410192888.7A Division CN118271391A (zh) 2016-06-17 2017-06-19 因子xa衍生物的制备
CN202310427500.2A Division CN116425860B (zh) 2016-06-17 2017-06-19 因子xa衍生物的制备

Publications (2)

Publication Number Publication Date
CN110167575A CN110167575A (zh) 2019-08-23
CN110167575B true CN110167575B (zh) 2024-03-15

Family

ID=60663351

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202310427500.2A Active CN116425860B (zh) 2016-06-17 2017-06-19 因子xa衍生物的制备
CN202410192888.7A Pending CN118271391A (zh) 2016-06-17 2017-06-19 因子xa衍生物的制备
CN201780041530.2A Active CN110167575B (zh) 2016-06-17 2017-06-19 因子xa衍生物的制备

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN202310427500.2A Active CN116425860B (zh) 2016-06-17 2017-06-19 因子xa衍生物的制备
CN202410192888.7A Pending CN118271391A (zh) 2016-06-17 2017-06-19 因子xa衍生物的制备

Country Status (21)

Country Link
US (4) US10604748B2 (enExample)
EP (3) EP3926044B1 (enExample)
JP (3) JP6959268B2 (enExample)
KR (1) KR102373215B1 (enExample)
CN (3) CN116425860B (enExample)
AU (2) AU2017283720C1 (enExample)
CL (2) CL2018003654A1 (enExample)
CO (1) CO2019000120A2 (enExample)
DK (1) DK3472314T3 (enExample)
EA (1) EA037815B1 (enExample)
ES (2) ES2875538T3 (enExample)
HU (1) HUE054597T2 (enExample)
IL (1) IL263591B2 (enExample)
MX (1) MX2018015873A (enExample)
PE (1) PE20190661A1 (enExample)
PH (1) PH12018502614A1 (enExample)
PL (1) PL3472314T3 (enExample)
PT (1) PT3472314T (enExample)
SG (1) SG11201810915QA (enExample)
SI (1) SI3472314T1 (enExample)
WO (1) WO2017219034A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8268783B2 (en) * 2007-09-28 2012-09-18 Portola Pharmaceuticals, Inc. Antidotes for factor Xa inhibitors and methods of using the same
SG10201705189XA (en) * 2013-01-24 2017-07-28 Portola Pharm Inc INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR Xa DERIVATIVES
ES2875538T3 (es) * 2016-06-17 2021-11-10 Alexion Pharma Inc Preparación de derivados del factor Xa
US12195774B2 (en) 2018-06-19 2025-01-14 Alexion Pharmaceuticals, Inc. Antidotes to factor XA inhibitors
KR102337683B1 (ko) * 2018-09-21 2021-12-13 주식회사 녹십자 고효율 항-tfpi 항체 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101802188A (zh) * 2007-09-28 2010-08-11 普托拉制药有限公司 用于因子xa抑制剂的解毒剂和其使用方法
US20140346397A1 (en) * 2012-12-27 2014-11-27 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
CN104379594A (zh) * 2012-06-14 2015-02-25 博尔托拉制药公司 用于纯化重组因子Xa衍生物的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5189019A (en) * 1990-04-23 1993-02-23 Merck & Co., Inc. Antistasin derived anticoagulant protein
US5589571A (en) 1994-10-28 1996-12-31 Cor Therapeutics, Inc. Process for production of inhibited forms of activated blood factors
JPH1066572A (ja) * 1996-08-29 1998-03-10 Showa Sangyo Co Ltd 高純度の大豆トリプシンインヒビターの製造方法
WO2001064642A2 (en) 2000-02-29 2001-09-07 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
ES2384116T3 (es) 2005-11-08 2012-06-29 Millennium Pharmaceuticals, Inc. Sales y polimorfos farmacéuticos de N-(5-cloro-2-piridinil)-2-[[4-[(dimetilamino)iminometil]benzoil]amino]-5-metoxi-benzamida, un inhibidor del factor XA
US8268783B2 (en) * 2007-09-28 2012-09-18 Portola Pharmaceuticals, Inc. Antidotes for factor Xa inhibitors and methods of using the same
US8455439B2 (en) 2008-11-14 2013-06-04 Portola Pharmaceuticals, Inc. Antidotes for factor Xa inhibitors and methods of using the same in combination with blood coagulating agents
ES2605801T3 (es) 2009-07-15 2017-03-16 Portola Pharmaceuticals, Inc. Formulación de dosis unitaria de antídoto para inhibidores del factor Xa para su uso en la prevención de la hemorragia
SG10201705189XA (en) * 2013-01-24 2017-07-28 Portola Pharm Inc INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR Xa DERIVATIVES
CN105579468A (zh) * 2013-09-24 2016-05-11 辉瑞大药厂 包含重组人凝血因子Xa蛋白的异质性群体的组合物
ES2814157T3 (es) * 2014-08-20 2021-03-26 Portola Pharm Inc Formulaciones liofilizadas para antídoto del factor Xa
ES2875538T3 (es) * 2016-06-17 2021-11-10 Alexion Pharma Inc Preparación de derivados del factor Xa

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101802188A (zh) * 2007-09-28 2010-08-11 普托拉制药有限公司 用于因子xa抑制剂的解毒剂和其使用方法
CN104379594A (zh) * 2012-06-14 2015-02-25 博尔托拉制药公司 用于纯化重组因子Xa衍生物的方法
US20140346397A1 (en) * 2012-12-27 2014-11-27 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Hydroxyapatite Chromatography: Purification Strategies for Recombinant Proteins;Cummings et al.;《Methods in Enzymology》;20141231;第541卷;第67-83页 *
Manufacturing process used to produce long-acting recombinant factor VIII Fc fusion protein;McCue et al.;《Biologicals》;20150617;第213-219页 *
Purification of factor X by hydrophobic interaction chromatography;Husi et al.;《Journal of Chromatography B》;20011231;摘要和材料与方法部分 *

Also Published As

Publication number Publication date
CN116425860B (zh) 2025-03-04
CN118271391A (zh) 2024-07-02
US10954504B2 (en) 2021-03-23
EP4588932A3 (en) 2025-10-01
JP6959268B2 (ja) 2021-11-02
BR112018075964A2 (pt) 2019-04-02
KR20190019134A (ko) 2019-02-26
PL3472314T3 (pl) 2021-11-22
EP3926044B1 (en) 2025-06-04
CL2018003654A1 (es) 2019-01-25
JP2019528242A (ja) 2019-10-10
PE20190661A1 (es) 2019-05-08
SI3472314T1 (sl) 2021-11-30
JP2022000477A (ja) 2022-01-04
ES2875538T3 (es) 2021-11-10
AU2017283720A1 (en) 2019-01-03
HUE054597T2 (hu) 2021-09-28
KR102373215B1 (ko) 2022-03-10
SG11201810915QA (en) 2019-01-30
WO2017219034A3 (en) 2019-03-14
US20200208131A1 (en) 2020-07-02
US20210348149A1 (en) 2021-11-11
JP7273918B2 (ja) 2023-05-15
ES3038834T3 (en) 2025-10-15
AU2017283720C1 (en) 2024-07-25
EA037815B1 (ru) 2021-05-25
IL263591B (en) 2022-11-01
AU2017283720B2 (en) 2022-11-17
EP3472314A4 (en) 2020-01-22
US20170369862A1 (en) 2017-12-28
PT3472314T (pt) 2021-06-18
EP3472314A2 (en) 2019-04-24
WO2017219034A2 (en) 2017-12-21
IL263591B2 (en) 2023-03-01
EP3926044A1 (en) 2021-12-22
EA201990052A1 (ru) 2019-05-31
CN116425860A (zh) 2023-07-14
JP2023086970A (ja) 2023-06-22
US20240076642A1 (en) 2024-03-07
IL263591A (en) 2019-02-03
CO2019000120A2 (es) 2019-03-29
AU2023200825A1 (en) 2023-03-16
CN110167575A (zh) 2019-08-23
PH12018502614A1 (en) 2019-09-30
CL2020001733A1 (es) 2020-09-25
US10604748B2 (en) 2020-03-31
DK3472314T3 (da) 2021-07-26
MX2018015873A (es) 2019-08-12
EP4588932A2 (en) 2025-07-23
US11845966B2 (en) 2023-12-19
CA3027457A1 (en) 2017-12-21
EP3472314B1 (en) 2021-05-05

Similar Documents

Publication Publication Date Title
JP7273918B2 (ja) 第ｘａ因子誘導体の調製
RU2731507C1 (ru) Gla домены в качестве нацеливающих агентов
EA002149B1 (ru) Улучшенные способы приготовления активированного белка с
AU2004290869A1 (en) Therapeutic use of factor XI
CA3027457C (en) Preparation of factor xa derivatives
HK40065948A (en) Preparation of factor xa derivatives
HK40006502B (en) Preparation of factor xa derivatives
WO2011058285A1 (fr) Procede de fabrication d'une preparation de facteur h
JP2007277094A (ja) 改変ダニ主要アレルゲン含有医薬組成物
BR122025008348A2 (pt) Produto polipeptídico expressado a partir de um construto de polinucleotídeo, composição farmacêutica e uso da referida composição farmacêutica
BR112018075964B1 (pt) Método para preparar um produto de polipeptídeo expressado a partir de um construto de polinucleotídeo, composição farmacêutica e uso da referida composição farmacêutica
WO2011058284A1 (fr) Preparation d'un concentre de facteur h
JP2008189574A (ja) 膵島移植補助薬剤
CZ373799A3 (cs) Zlepšené způsoby zpracování aktivovaného proteinu C
JPH04182436A (ja) 医薬組成物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: California, USA

Applicant after: Bortola Pharmaceutical Co.,Ltd.

Address before: California, USA

Applicant before: PORTOLA PHARMACEUTICALS, Inc.

CB02 Change of applicant information
TA01 Transfer of patent application right

Effective date of registration: 20230420

Address after: Massachusetts

Applicant after: ALEXION PHARMACEUTICALS, Inc.

Address before: California, USA

Applicant before: Bortola Pharmaceutical Co.,Ltd.

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant